Articles tagged with Colon Cancer
The ERASur clinical trial is investigating whether total ablative therapy can improve overall survival in patients with newly diagnosed, limited metastatic colorectal cancer. The study has reached one-third patient accrual milestone, signaling strong momentum.
Researchers at the Sylvester Comprehensive Cancer Center presented several studies at ASCO 2026 exploring new treatment options for patients with advanced gastrointestinal stromal tumors (GISTs) and melanoma. These include velzatinib, a targeted therapy for GIST patients, and PRAME-directed T-cell receptor therapies for synovial sarcoma.
A randomized controlled trial found that a 1 L PEG-ascorbate regimen provided effective and high-quality bowel cleansing, while being associated with a greater willingness to repeat the regimen compared to 2 L and 4 L PEG regimens. The findings support adopting a low-volume regimen to improve completion rates and patient tolerability.
A study finds that rectal cancer mortality is increasing rapidly among adults under 45, with Hispanic and Western US populations experiencing the steepest rises. The study calls for earlier screening and increased awareness to combat this growing trend.
Colorectal cancer incidence is rising among young individuals in Switzerland, with cancers occurring before age 50 accounting for 6.1% of all cases. The study highlights the importance of awareness and earlier screening to address this trend.
Researchers found that sleep deprivation alters the composition of gut microbiota, leading to worse cancer progression and reduced effectiveness of chemotherapy. The study highlights the importance of maintaining a healthy microbiome through good sleep and diet.
A randomized trial found that duloxetine does not prevent painful neuropathy caused by oxaliplatin-based chemotherapy in patients with stage II or III colorectal cancer. The study suggests that duloxetine should only be used for managing existing neuropathy, not prevention.
The Alliance for Clinical Trials in Oncology is enrolling adolescent and young adult cancer patients in various trials, including genetic services and treatment studies. These trials aim to address longstanding gaps in care and improve outcomes for AYAs with cancer.
Researchers at University of Liège develop mouse model to study Stard7's role in intestinal cancers, revealing protein's dual effects on tumour development. In some cases, Stard7 deficiency reduces tumour growth, while in others it accelerates it.
Researchers at Mayo Clinic found that adding immunotherapy to chemotherapy after surgery for patients with stage 3 (node-positive) colon cancer reduced cancer recurrence and mortality by 50% compared to chemotherapy alone. The study used an immune checkpoint inhibitor, atezolizumab, to reactivate a person's anti-tumor immunity.
A study in mice reveals that chronic intestinal inflammation can lead to epigenetic 'memories' that promote colon cancer. Researchers found that even seemingly healed gut tissues retain molecular scars from earlier inflammation, making it easier for cancer to take hold.
Researchers have developed a novel approach to fight colorectal cancer using modified Listeria bacteria as a courier to deliver potent cancer-killing proteins into tumor cells. This method has shown significant anti-tumor activity and could potentially lead to the development of a safe and effective oral treatment.
The Alliance for Clinical Trials in Oncology is spotlighting new trials for colorectal cancer in March, focusing on early detection methods and treatments for treatment delays and loss of appetite. The trials aim to improve patient outcomes, with several enrolling patients with newly diagnosed colon or rectal cancer.
A new clinical study aims to improve communication between patients and families about genetic risks of colorectal cancer. The trial will compare two methods of sharing genetic test results with close relatives, with the goal of learning which approach helps more family members get necessary genetic testing.
The King Center for Lynch Syndrome will advance research, outreach, education, and patient care for Lynch syndrome, a hereditary condition affecting 1 in 279 individuals. The center will provide cutting-edge research, life-long comprehensive care, and increased awareness for patients and families affected by Lynch syndrome.
This study investigates the clinicopathologic features and genomic landscape of DNA polymerase epsilon mutant colorectal adenocarcinomas. The analysis reveals two distinct subgroups with different outcomes, suggesting improved prognostication for some patients.
A study by University of Texas at Dallas bioengineers found that both cancerous and noncancerous colon tissue from young patients with colorectal cancer was mechanically stiffer than in older patients. This stiffness may promote the development of early-onset colorectal cancer, a condition rising over the past 30 years.
A new analysis found that rural cancer patients treated locally have similar surgical outcomes to those who traveled to urban facilities. The study used Surveillance, Epidemiology, and End Results data from Medicare-eligible patients with lung or colon cancer, aged 65 or older, residing in rural areas.
Researchers developed an AI tool called ONCO-ACS to predict the risk of secondary heart attacks in cancer patients after a heart attack. The tool combines cancer-related factors with standard clinical data to provide reliable information for doctors to balance treatment benefits and harms.
Research reveals that higher lifetime alcohol consumption is associated with a higher risk of colorectal cancer, especially for rectal cancer. Quitting drinking can lower a person’s risk, according to the findings published in CANCER, a peer-reviewed journal.
Predictions for lung cancer death rates among EU and UK women indicate stabilization of mortality rates at 12.5 deaths per 100,000 in 2026. Lung cancer remains the leading cause of cancer death for both sexes in the EU, with mortality rates continuing to decline among men.
A new clinical trial, PAGODA, seeks to minimize treatment interruptions and help patients complete their chemotherapy as planned. The trial will test a structured plan to guide doctors in making small, proactive changes to chemotherapy doses to prevent treatment delays.
A new study found that bowel preparation procedures for colonoscopies can disrupt the gut environment, making mice more susceptible to infection and inflammation. The researchers hope to understand whether these procedures may put people with inflammatory bowel disease (IBD) at risk of exacerbation.
A recent study published in Gut journal revealed that Streptococcus anginosus produces methionine metabolites, which significantly contribute to the development of gastric cancer. The research opens new paths for microbiota-targeted prevention strategies.
Research from Florida Atlantic University strengthens evidence that alcohol consumption increases cancer risk, particularly for breast, colorectal, and liver cancers. Higher intake and specific groups, such as African Americans and those with obesity or diabetes, are found to be more vulnerable to the risks.
Scientists at Penn Vet have identified two genes, Ctnna1 and Bcl2l13, that suppress metastasis in preclinical models of colorectal cancer. These findings could lead to better treatments and therapies for patients with metastatic disease.
Researchers found that fewer than 1 in 4 eligible younger adults completed colorectal cancer screenings after the USPSTF lowered the recommended screening age to 45. Despite investigating unmet social needs, no significant differences were found in testing uptake for this early midlife cohort.
Researchers developed a new DNA analysis technique to study old genetic samples, shedding light on disease evolution and changes in biology over time. The approach has potential for unlocking the root causes underlying shifting landscapes of modern diseases.
A recent study published in Cancer Investigation found that GLP-1 receptor agonists significantly reduced the risk of death among colon cancer patients. The analysis of over 6,800 patients revealed a nearly 50% lower likelihood of death within five years compared to non-users.
A blood test detecting tiny fragments of cancer DNA can help tailor chemotherapy to individual patients with stage 3 colon cancer. The DYNAMIC-III study found that patients with low-risk levels had an 87% cancer-free rate three years after surgery, while those with high-risk levels had a much higher risk of recurrence.
The study found that using circulating tumor DNA to guide treatment resulted in fewer recurrences, hospitalizations, and treatment side effects among patients who tested negative for ctDNA. Patients with positive results did not see improved outcomes from escalated therapy.
Researchers from A*STAR Institute of Molecular and Cell Biology have identified two critical stem cell populations that drive colorectal cancer formation in different colon regions. The study reveals how NOX1 and NPY1R proteins mark distinct stem cell populations, providing new targets and models for developing region-specific cancer t...
Researchers at UCSF have discovered a novel combination of immunotherapies that can reprogram the immune environment of colon cancer tumors in the liver. This therapy often eliminated tumors entirely in preclinical models, showing promise for treating patients with advanced colorectal cancer.
Researchers found that rectal bleeding increases the odds of a colorectal cancer diagnosis by 8.5 times in patients under 50, highlighting the need for symptom-driven care and lifestyle modifications to reduce the risk. The study analyzed 443 patients and identified no family history as a factor in early-onset colorectal cancers.
Researchers identified a cellular mechanism that alters the gut microbiome in a way that promotes cancer. Long-chain fatty acids serve as food for certain bacteria, such as Desulfovibrio fairfieldensis, which multiply and displace other microbes.
Recent clinical trials demonstrate the potential benefits of neoadjuvant chemotherapy and immunotherapy in improving tumor response and surgical success for patients with locally advanced colon cancer. The approach also reduces the risk of recurrence and metastasis, increasing survival outcomes and decreasing cancer-related complications.
A randomized clinical trial shows that low-dose aspirin reduces the risk of recurrence by 55% in patients with colon and rectal cancer harboring a specific genetic mutation. Aspirin's anti-inflammatory and anti-tumor effects may be responsible for its therapeutic benefits.
The Alliance for Clinical Trials in Oncology will host a public webinar showcasing key findings from the 2025 ASCO Annual Meeting. Researchers will discuss latest information on colorectal, squamous cell, and renal cell cancers.
A new study found that providing personalized colorectal cancer risk information to patients and their health care providers did not improve screening rates for the deadly ailment. Colorectal cancer is the second-most common cause of death from cancer in the United States, claiming nearly 55,000 lives annually.
Researchers analyzed data from 33,183 individuals and found that minimally invasive approach was associated with lower complication risks compared to open surgery. This study suggests that expanded use of minimally invasive surgery in rural areas may help bridge the gap between rural and urban patients with colon cancer.
The foundation provides $300,000 total funding over four years to investigate cancer causes, mechanisms, therapies, and prevention. This support fosters interdisciplinary research and encourages innovative projects that push boundaries and make breakthroughs.
Autistic adults face barriers to colonoscopies due to sensory and communication challenges, yet are less likely to receive the critical diagnostic procedure. Boston University's project aims to engage autistic voices through a national advisory board and patient-centered comparative clinical effectiveness research.
A new study suggests platelets play a role in limiting systemic inflammation and may offer an untapped source of cancer DNA for early detection, potentially improving the sensitivity of liquid biopsies.
Scientists have developed a monoclonal antibody to combat life-threatening inflammatory diseases like sepsis and ARDS. The antibody shows promise in blocking the immune system's hyperactive response and restoring healthy function without unwanted side effects.
A nationwide Swedish study found nearly three times as many young adults under 50 diagnosed with colorectal cancer today compared to the early 1990s. The disease has become two to three times more common in this age group, with underlying causes not fully understood.
A study published in The Lancet Gastroenterology & Hepatology found that routine AI assistance during colonoscopies can lead to a decrease in the ability of endoscopists to detect precancerous growths without AI aid. This reduction in skills may impact patient-related outcomes and highlight the need for further research on the long-ter...
Researchers have developed a novel technology that can simultaneously silence two notoriously difficult-to-target cancer-related genes, KRAS and MYC. This innovation has the potential to treat cancers that have been challenging to treat, with significant implications for patients.
Researchers found that automatically mailing a stool-based screening test resulted in the highest screening rates among adults aged 45-49. The study, which included over 20,000 patients, showed that this approach can encourage timely screening and potentially save lives.
Researchers uncover more clues about the risk conferred by variants in the MUTYH gene, which can cause abnormal growths and increase colon cancer risk. The study's high-throughput functional analysis method accurately sorts variants into functional and non-functional categories.
Researchers at ETH Zurich and Stanford University quantified the number of molecules produced by gut bacteria that reach the human body daily. This knowledge helps understand how the gut microbiome influences health and behavior.
Researchers have identified CDX1 and CDX2 as key molecules that counteract β-catenin and suppress stemness in colon cancer. Deletion or overexpression of these proteins increased tumor aggressiveness and expression of cancer stemness-related genes, suggesting a potential therapeutic target.
Early-onset gastrointestinal cancers are rising globally, particularly among younger adults. Colorectal cancer is the most common early-onset GI cancer, accounting for over half of cases, and its incidence is increasing faster than any other type of early-onset cancer.
A 1,000-patient clinical study will use RNA-based stool and saliva tests to detect colon polyps, enabling early prevention of colorectal cancer. The study aims to develop an at-home RNA test that empowers people to take action before cancer takes hold.
The study highlights a significant increase in early-onset colorectal cancer rates globally, particularly in high-income countries. Younger patients are more likely to receive aggressive treatment without survival advantage, and survivors often report problems with anxiety, body image, and sexual dysfunction.
Researchers found that combining selinexor with Irinotecan shrunk tumors in preclinical models of colorectal cancer, suggesting a new potential treatment. The study also identified XPO1 mutations linked to rare cancers like endometrial cancer and found that these mutations make cells resistant to chemotherapy.
A study published in Radiology found that CT colonography is more effective and cost-effective than stool DNA testing for colorectal cancer screening, reducing incidence by 70-75% compared to 59%. CT colonography is also a cost-saving option with an estimated cost of $9,000 per QALY gained.
A study found significant gaps in testing for genetic cancer risk among patients with womb cancer, with less than half eligible receiving a blood test for Lynch syndrome. This can lead to delayed diagnosis and increased cancer risk, affecting not only the individual but also their family members.
A study found slightly lower adenoma detection rates in adults aged 45-49 compared to older groups, consistent with previous evaluations of screening colonoscopies. The study's findings suggest that the lowered screening age may have a beneficial effect on colon cancer prevention.
A phase 3 trial of patients with surgically resected stage 3 dMMR colon cancer found that adding an immune checkpoint inhibitor (atezolizumab) to standard chemotherapy improved disease-free survival by 50% compared to chemotherapy alone. The study results provide new evidence for a treatment approach in this high-risk patient population.
Charité researchers identified a therapeutic target that significantly contributes to halting ongoing inflammatory processes. They found that interleukin-22 and oncostatin M drive inflammation by amplifying the immune response. Targeted treatments may help high-risk patients, but chronic diseases remain complex and difficult to predict.